Article
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
British journal of haematology - 1 May 2012
Coude Marie-Magdelaine, Luycx Odile, Cariou Marie-Estelle, Maarek Odile, Dombret Hervé, Cayuela Jean-Michel, Rea Delphine
Abstract excerpt
No abstract is available from the source.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.